Please login to the form below

Not currently logged in
Email:
Password:

Sanofi sheds jobs in R&D restructuring

New R&D chief diverting funds to new therapy areas

sanofi

Hundreds of jobs are to go at Sanofi’s research and development facilities in France and Germany.

466 jobs will be cut, with diabetes and cardiovascular R&D bearing the brunt of the restructuring at the French pharma company. The job cuts will mostly be in France, but reductions will also hit Germany.

Making job cuts isn't as easy to do in these countries as it is in the US, and the company is now entering into consultations with unions, while stressing that it plans to maintain a long-term commitment to both France and Germany.

Sanofi plans to add new headcount in France, Germany and the US in other disciplines, and will divert resources to expanding work in other therapeutic areas. The company’s cuts in diabetes reflect difficulties in finding new treatments superior to existing ones – led by its insulin analogue blockbuster Lantus, which is now in steep decline because of biosimilars in Europe and price pressures in the US.

The FDA also recently rejected its Lexicon partnered SGLT1/SGLT2 inhibitor Zynquista.

Sanofi’s restructuring of its R&D organisation is headed by John Reed, its new R&D chief, who joined from Roche last year.

jr

John Reed

He commented: “The transformation of our R&D organisation would enable us to focus on the therapeutic areas and platforms where we believe we have the greatest opportunity to make a meaningful difference for patients and to maximise the productivity of our research engine.”

The R&D pipeline review will allow Sanofi to re-focus its prioritised therapeutics areas. It has 84 projects in its pipeline, with oncology accounting for 26 projects. Immuno-inflammation represents 19 projects, and vaccines comes in third with 11. Out of these projects, 28 are in phase 3 trials, and seven in the registration stage.

The company has also just announced a change of CEO - Novartis pharma chief Paul Hudson will take over from Olivier Brandicourt from 1 September.

Article by
Lucy Parsons

21st June 2019

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
wearable health tech
A cultural shift in clinical research
Research organisations across the board are experimenting with new technologies...

Infographics